Oppenheimer lowered the firm’s price target on Sagimet Biosciences (SGMT) to $25 from $30 and keeps an Outperform rating on the shares.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet Biosciences Reports Q1 2025 Financial Results
- Sagimet Biosciences Reports Q1 Financial Results and Updates
- Sagimet Biosciences reports Q1 EPS (56c), consensus (69c)
- Sagimet Biosciences announces presentations at EASL Congress 2025
- Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position